Rates of diagnosis and treatment are low, so there is need for diagnostic tests and biomarkers for classification and ...

Patient demonstrations, ongoing clinical trials and heavy investment signal that BCIs could be commercialised by 2030.

Elicio's mKRAS-targeting cancer vaccine reduced the risk of death by 77% by activating the anti-tumour mechanisms of key ...

Marea Therapeutics has enrolled the first subject in the MAR-201 Phase I trial of MAR002, aimed at treating acromegaly.

Newron has randomised the first participants in its ENIGMA-TRS 1 Phase III programme of evenamide for treatment-resistant ...

Response is also considering running trials of the weight management drug RDX-002 in combination with GLP-1RA therapies.

The FDA has given the green light for Tiziana Life Sciences’ IND to advance its Phase IIa study of intranasal foralumab for ...

In the Phase III trial, the combination of Padcev and Keytruda improved event-free survival and overall survival in MIBC.

Novartis' mAb ianalumab helped maintain safe platelet levels for a prolonged period, reducing patient reliance on hospital ...

Palisade Bio has reported positive outcomes from the Phase Ib open-label cohort of PALI-2108 in those with moderate-to-severe UC.

NHS England is set to offer expedited access to the trial for BioNTech’s new cancer vaccine, BNT113-01, for individuals with advanced head and neck cancers.

If approved, Novartis' ianalumab would become the first targeted treatment for patients with Sjögren’s disease.